Mode
Text Size
Log in / Sign up
N/A N=63 Treatment

Adaptability and Resilience in Aging Adults-2

Aging · Chronic Low-back Pain

Enrolled (actual)
63
Serious AEs
0.0%
Results posted
Jul 2024
Primary outcome: Primary: Session-level Engagement — 6.3 score on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Resilience Intervention (Behavioral)
Age
Adult, Older Adult · 60+ yrs
Sex
All
Sponsor
University of Florida
Primary completion
May 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Session-level Engagement
6.3
PRIMARY
Treatment Satisfaction
3.4
PRIMARY
Treatment Credibility and Expectancy
7.7
PRIMARY
Satisfaction With Intervention Content
2.9
PRIMARY
Intervention Commencement Rate
59
PRIMARY
Participant Retention
50
PRIMARY
Questionnaire Feasibility
96.8
PRIMARY
Home Activity Feasibility
4.6

Summary

Chronic low back pain is a major health concern among older adults and is associated with increased economic, functional, and psychological burden. Resilience has been highlighted as a crucial factor in positive health-related functioning, and a growing body of literature supports the use of resilience-based interventions in chronic pain. Therefore, the goals of this project are to examine the feasibility and acceptability of a resilience intervention for chronic low back pain among older adults.

Eligibility Criteria

Inclusion Criteria

  • Age 60 and older
  • Low back pain on at least half the days over the previous 6 months
  • Average daily back pain score ≥3 on a 0-10 numerical rating scale
  • At least moderate (≥3/10) CLBP-related interference on a 0-10 numerical rating scale
  • Able to read/write in English

Exclusion Criteria

  • Current participation in another psychological treatment
  • Severe psychiatric illness not adequately controlled by medication (e.g., schizophrenia, bipolar disorder) or other conditions anticipated to impair intervention engagement (e.g., substance abuse/dependence)
  • Presence of chronic, malignant pain (e.g., HIV, cancer) or systemic inflammatory disease (e.g., rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, etc.)
  • Significant cognitive impairment on the MoCA
  • If currently taking prescription analgesic or psychotropic medication, must be stabilized on these treatments for ≥4 weeks prior to the baseline assessment
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04068922). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search